AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33803576 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls (24H FV)
Number of subjects: 177
Study 33803576 — intervention group
Group type: COMPARATOR
Intervention: National Cancer Institute’s All‐Day Fruit and Vegetable Screener (NCI FV)
Number of subjects: 177
Study 35785559 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture (10-week bilateral treatment of ST34, EX–LE12, and EX–LE8)
Number of subjects: 60
Study 35785559 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 60
Study 35785559 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 60
Study 34373044 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide (50 mg/day) for 3 months
Number of subjects: 30
Study 32604381 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care (n = 128) with routine radiographs at 6 and 12 weeks
Number of subjects: 246
Study 32604381 — intervention group
Group type: COMPARATOR
Intervention: Reduced-imaging group (n = 118) without routine radiographs at 6 and 12 weeks
Number of subjects: 246
Study 32604381 — intervention group
Group type: COMPARATOR
Intervention: Reduced-imaging group
Number of subjects: 246
Study 32604381 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 246
Study 35229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy followed by postoperative physiotherapy
Number of subjects: 348
Study 35229713 — intervention group
Group type: COMPARATOR
Intervention: Personalised hip therapy (individualised physiotherapist-led programme of conservative care)
Number of subjects: 348
Study 33879328 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard I COUGH education along with text message reminders to ambulate postoperatively
Number of subjects: 0
Study 33879328 — intervention group
Group type: COMPARATOR
Intervention: Standard education alone
Number of subjects: 0
Study 32743968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalla Bona attachments
Number of subjects: 24
Study 32743968 — intervention group
Group type: COMPARATOR
Intervention: Locator attachments
Number of subjects: 24
Study 35538242 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendation from the World Health Organization (PAR)
Number of subjects: 66
Study 35538242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 66
Study 35538242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training with whole-body electromyostimulation (HIIT + EMS)
Number of subjects: 66
Study 35538242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 66
Study 33682457 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein intake (∼1.0 g·kg‐1·day‐1) during resistance training
Number of subjects: 50
Study 33682457 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (∼1.6 g·kg‐1·day‐1) during resistance training
Number of subjects: 50
Study 33682457 — intervention group
Group type: COMPARATOR
Intervention: Both MOD and HIGH protein intake
Number of subjects: 50
Study 32658754 — intervention group
Group type: EXPERIMENTAL
Intervention: National protocol: initial dose of 100 ml followed by 100 ml 6th hourly until 20WBCT was negative or 300 ml of ASV was given, whichever was earlier
Number of subjects: 140
Study 32658754 — intervention group
Group type: COMPARATOR
Intervention: Current protocol: 70 ml followed by 30 ml every 6th hourly until two consecutive 20WBCT were negative
Number of subjects: 140
Study 32658754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 32658754 — intervention group
Group type: EXPERIMENTAL
Intervention: National ASV dosing protocol
Number of subjects: 140
Study 36432526 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 20
Study 36432526 — intervention group
Group type: COMPARATOR
Intervention: Control (no substance ingestion)
Number of subjects: 20
Study 32975705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1100 ppm fluoride as NaF, 0.61% green tea extract, or 0.012% chlorhexidine digluconate
Number of subjects: 23
Study 32975705 — intervention group
Group type: EXPERIMENTAL
Intervention: Gels containing 400 μM EGCG, 0.012% chlorhexidine, 1 mM FeSO4, 1.23% F (NaF)
Number of subjects: 23
Study 32975705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32975705 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 23
Study 34233094 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses (OKL)
Number of subjects: 60
Study 34233094 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacles (SVS)
Number of subjects: 60
Study 34696742 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Number of subjects: 202
Study 34696742 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Number of subjects: 202
Study 34696742 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Number of subjects: 202
Study 34696742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 36261169 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 3561
Study 36261169 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography
Number of subjects: 3561
Study 33606692 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable common mental disorders (CMD)
Number of subjects: 220
Study 33606692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger among those who reported intimate partner violence (IPV)
Number of subjects: 220
Study 33606692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger among those who did not report IPV
Number of subjects: 220
Study 32516291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 44
Study 32516291 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide 30 mg/day
Number of subjects: 44
Study 36377016 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiologic gastrostomy (PRG)
Number of subjects: 60
Study 36377016 — intervention group
Group type: COMPARATOR
Intervention: Nasal feeding tube (NFT)
Number of subjects: 60
Study 32012166 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating single file followed by matching-taper single-cone filling
Number of subjects: 120
Study 32012166 — intervention group
Group type: COMPARATOR
Intervention: Hand file and lateral compaction filling
Number of subjects: 120
Study 35917508 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT with 0.07% methylene blue as photosensitizer and laser irradiation (λ660 nm, power 40 mW, 5 min)
Number of subjects: 40
Study 35917508 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (λ2940 nm, 15 Hz, 100 mJ)
Number of subjects: 40
Study 35917508 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + PDT
Number of subjects: 40
Study 35917508 — intervention group
Group type: COMPARATOR
Intervention: 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 40
Study 33151847 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive 360° video viewed through head-mounted displays (HMDs)
Number of subjects: 107
Study 33151847 — intervention group
Group type: COMPARATOR
Intervention: Immersive 360° video viewed through tablets
Number of subjects: 107
Study 33070361 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe OSA
Number of subjects: 72
Study 32727392 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from nephrologists (co-management by primary care physicians and nephrologists)
Number of subjects: 242
Study 32727392 — intervention group
Group type: COMPARATOR
Intervention: Managed by primary care physicians with written instructions and nephrology consultations on demand
Number of subjects: 242
Study 35531644 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Fundoscopy (SF)
Number of subjects: 79
Study 35531644 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mydriatic Fundus Photography (NMFP)
Number of subjects: 79
Study 35531644 — intervention group
Group type: COMPARATOR
Intervention: Routine Fundoscopic Practice (Control)
Number of subjects: 79
Study 32350320 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 59
Study 32350320 — intervention group
Group type: COMPARATOR
Intervention: Sham-TENS
Number of subjects: 59
Study 33413320 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus SP1)
Number of subjects: 47
Study 33413320 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 47
Study 33413320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 33413320 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Probiotics, Azithromycin, and Placebo)
Number of subjects: 47
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: nabiximols
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: counselling attendance
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: higher dose of nabiximols
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: longer duration of regular cannabis use
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: greater quantity of cannabis use
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: greater pain at baseline
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: more severe sleep issues
Number of subjects: 128
Study 36209081 — intervention group
Group type: EXPERIMENTAL
Intervention: males
Number of subjects: 128
Study 33390421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise plus 5 mg (up to 10 mg) of dapagliflozin daily (IT group)
Number of subjects: 146
Study 33390421 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin alone (CT group)
Number of subjects: 146
Study 33390421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise plus dapagliflozin (IT group)
Number of subjects: 146
Study 35147302 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g/day n‐3‐PUFA
Number of subjects: 60
Study 35147302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32757287 — intervention group
Group type: EXPERIMENTAL
Intervention: True NIAPs
Number of subjects: 56
Study 32757287 — intervention group
Group type: COMPARATOR
Intervention: Sham NIAPs
Number of subjects: 56
Study 33675013 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength exercise (twice weekly for 10 weeks) with educational materials, exercise equipment (dumbbells, resistance bands), and video coaching support.
Number of subjects: 40
Study 33675013 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 40
Study 32978076 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-naproxen-oseltamivir combination therapy
Number of subjects: 54
Study 32978076 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir alone
Number of subjects: 54
Study 36455504 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI (35 mg/m2 twice daily days 1‐5 and 8‐12, 28‐day cycle)
Number of subjects: 868
Study 36455504 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 868
Study 36455504 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 868
Study 32479701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (25(OH)D <50nmol/L)
Number of subjects: 851
Study 32479701 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D sufficient (25(OH)D ≥50nmol/L)
Number of subjects: 851
Study 36352326 — intervention group
Group type: EXPERIMENTAL
Intervention: One-page educational graphic providing facts and benefits regarding COVID-19 vaccination
Number of subjects: 1103
Study 36352326 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 1103
Study 36352326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MMI scores
Number of subjects: 1103
Study 36352326 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-7 and PHQ-8 scores
Number of subjects: 1103
Study 36352326 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment initiation after March 2020
Number of subjects: 1103
Study 33452295 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker (timolol maleate) and/or prostaglandin analog (latanoprost)
Number of subjects: 151
Study 33452295 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 151
Study 35065786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational programme including education about root-cause analysis and care bundles (4-month duration)
Number of subjects: 3454
Study 35065786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3454
Study 32815991 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 227
Study 32815991 — intervention group
Group type: COMPARATOR
Intervention: Open total gastrectomy (OTG)
Number of subjects: 227
Study 33998053 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed Mendelian randomization method
Number of subjects: 0
Study 33998053 — intervention group
Group type: COMPARATOR
Intervention: Wald method
Number of subjects: 0
Study 33998053 — intervention group
Group type: COMPARATOR
Intervention: Two-stage predictor substitution (2SPS)
Number of subjects: 0
Study 33998053 — intervention group
Group type: COMPARATOR
Intervention: Two-stage residual inclusion (2SRI)
Number of subjects: 0
Study 33998053 — intervention group
Group type: COMPARATOR
Intervention: Generalized method of moments (GMM)
Number of subjects: 0
Study 33998053 — intervention group
Group type: COMPARATOR
Intervention: Ever smoking
Number of subjects: 0
Study 32937008 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ACEI or ARB
Number of subjects: 0
Study 32937008 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of ACEI or ARB
Number of subjects: 0
Study 35701454 — intervention group
Group type: EXPERIMENTAL
Intervention: wMel Wolbachia intervention in Aedes aegypti mosquito population
Number of subjects: 318
Study 35701454 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 318
Study 35701454 — intervention group
Group type: EXPERIMENTAL
Intervention: wMel Wolbachia intervention
Number of subjects: 318
Study 34028647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on routine biochemical variables including female gender, serum potassium, serum calcium-phosphorus product, and urine pH.
Number of subjects: 806
Study 34028647 — intervention group
Group type: COMPARATOR
Intervention: Other known prediction models (control group).
Number of subjects: 806
Study 36069505 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml ropivacaine 0.5%
Number of subjects: 32
Study 36069505 — intervention group
Group type: COMPARATOR
Intervention: 20 ml ropivacaine 0.5%
Number of subjects: 32
Study 33947390 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate 0.1 mg/day
Number of subjects: 1253
Study 33947390 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate 0.2 mg/day
Number of subjects: 1253
Study 33947390 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate 0.4 mg/day
Number of subjects: 1253
Study 33947390 — intervention group
Group type: EXPERIMENTAL
Intervention: pemafibrate (all doses)
Number of subjects: 1253
Study 33947390 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1253
Study 32935191 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-to-recipient gender mismatched (male donor to female recipient)
Number of subjects: 546
Study 32935191 — intervention group
Group type: COMPARATOR
Intervention: Matched patients
Number of subjects: 546
Study 33250209 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 888
Study 33250209 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 888
Study 33250209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study 33250209 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (all doses)
Number of subjects: 888
Study 33054635 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with restricted calorie diet (RCD) for 12 weeks
Number of subjects: 62
Study 33327340 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA), administered 2 times a week for 4 weeks.
Number of subjects: 112
Study 33327340 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific intervention not detailed in the abstract).
Number of subjects: 112
Study 35749925 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 99
Study 35749925 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 99
Study 34714398 — intervention group
Group type: EXPERIMENTAL
Intervention: White-opaque flowable composite liner
Number of subjects: 100
Study 34714398 — intervention group
Group type: COMPARATOR
Intervention: Tooth-colored composite (control)
Number of subjects: 100
Study 33528372 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tutorial (OT) only group
Number of subjects: 624
Study 33528372 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tutorial plus motivational interviewing (OT-MI) group
Number of subjects: 624
Study 33528372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 624
Study 32266988 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIRATE 2020 guidelines implementation
Number of subjects: 0
Study 32266988 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 35705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone recruitment strategy
Number of subjects: 1624
Study 35705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Email recruitment strategy
Number of subjects: 1624
Study 35705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message recruitment strategy
Number of subjects: 1624
Study 35705390 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of girls
Number of subjects: 1624
Study 34111865 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic cannulae
Number of subjects: 90
Study 34111865 — intervention group
Group type: COMPARATOR
Intervention: Metal needles
Number of subjects: 90
Study 36103719 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical vestibular stimulation (n=15) administered for 12 weeks
Number of subjects: 30
Study 36103719 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (Control group, n=15)
Number of subjects: 30
Study 34386216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical emollient therapy with sunflower seed oil (SSO)
Number of subjects: 20
Study 32726666 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation (iTBS) over dorsomedial prefrontal cortex (dmPFC)
Number of subjects: 30
Study 32726666 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 30
Study 35091522 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 128
Study 35091522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 34629300 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + Metformin (D+M)
Number of subjects: 99
Study 34629300 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel + Placebo (D+P)
Number of subjects: 99
Study 33321381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/day)
Number of subjects: 413
Study 33321381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 33321381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 413
Study 35797166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 173
Study 35797166 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 173
Study 34422293 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport participation
Number of subjects: 128
Study 34422293 — intervention group
Group type: COMPARATOR
Intervention: Group circuit training
Number of subjects: 128
Study 32669161 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic caffeine citrate
Number of subjects: 98
Study 32669161 — intervention group
Group type: COMPARATOR
Intervention: Imported caffeine citrate
Number of subjects: 98
Study 33688928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower expression of the angiotensin-converting enzyme (ACE) gene in blood
Number of subjects: 40675
Study 33688928 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE expression in prefrontal cortex
Number of subjects: 40675
Study 33688928 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE protein levels in cerebral spinal fluid
Number of subjects: 40675
Study 33688928 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE protein levels in plasma
Number of subjects: 40675
Study 33688928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure associated with lower ACE expression
Number of subjects: 40675
Study 32825565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototypes of Tobacco Users Scale (POTUS) for cigarette smokers
Number of subjects: 1414
Study 32825565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototypes of Tobacco Users Scale (POTUS) for e‐cigarette users
Number of subjects: 1414
Study 32825565 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative prototypes at baseline
Number of subjects: 1414
Study 35323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (0.1 mg subcutaneous GnRH agonist)
Number of subjects: 163
Study 35323085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no luteal phase support)
Number of subjects: 163
Study 35323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin with ovarian stimulation using letrozole
Number of subjects: 163
Study 35323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin with gonadotrophin added to letrozole
Number of subjects: 163